Non-viral, large-scale delivery of gene editing tools for T cell manufacturing

Thursday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Non-viral, large-scale delivery of gene editing tools for T cell manufacturing

Amongst non-viral methods for cell engineering, electroporation is considered the gold standard, with an increasing presence in clinical trials. Achieving efficient electroporation of clinically relevant cargos into large volumes of T cells is critical for developers in the field.

The expert panel will demonstrate how optimal parameters for cell handling established in small scale can be successfully adapted into a new large-scale cartridge format, enabling the efficient transfection of up to one billion cells from research to GMP-manufacturing. The transfection specialists will focus on the delivery of gene editing tools, including CRISPR and transposon-based integration methods.

Join the webinar and learn how this innovation forms a robust and scalable technology platform that holds significant promise for applications in the CGT space.

Attend this webinar to:

Find out how to achieve reliable, robust and efficient delivery of different cargo types from DNA and mRNA to complex, clinically relevant cargos for CRISPR knock-out/knock-in (RNPs) or transposon-based integration
See how to easily scale up your cell engineering process to 1 billion T cells with more than 90% knock-out and up to around 40% knock-in or transposition
Learn about the versatility of the setup in terms of process parameters, starting material and cargo

Stefanie Müthel

R&D Team Lead at Lonza Cologne

Stefanie Muethel joined Lonza in 2025 as a Team Lead in R&D where she and her team focus on optimizing gene editing technologies such as CRISPR/Cas9 and transposon-based integration for large-scale transfection with the 4D-Nucleofector® LV Unit PRO, supporting therapy developments in cell and gene therapy.

Before joining Lonza, Dr. Muethel held a position at the Charité - Universitätsklinikum Berlin to develop a CRISPR/Cas9-based ex vivo stem cell therapy approach for muscular dystrophy patients where she combined different gene editing tools using the Nucleofector® Technology. She completed her PhD at the Berlin Institute for Medical Systems Biology characterizing an epigenetic regulator in the nematode C. elegans.

Andrea Toell

Senior Product Manager at Lonza Cologne

Andrea Toell is a Senior Product Manager at Lonza Cologne GmbH and is currently responsible for Lonza's Nucleofector® Transfection Portfolio. In her current role she is focusing on large volume transfection and cell and gene therapy applications (CAR-T cells, genome editing, GMP manufacturing). In her 20 years' experience with the technology she gained a broad knowledge about transfection technologies and factors that are important for successful transfection experiments.

Andrea joined the Lonza team (legacy amaxa) as Scientific Support Specialist in 2001 before moving into Product Management in 2004. She holds a Diploma in Biology from the University of Münster, Germany, and a PhD in Biology from the University of Düsseldorf, Germany.

You have registered for this webinar